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angina, stroke, post-stroke, heart failure and death. It has an
annual cycle and estimates mean quality-adjusted survival and
treatment cost, which reﬂects hypertension treatment and the
management of cardiovascular events. Risk functions were used
to conduct extrapolations. Data on treatment effectiveness,
quality-of-life and epidemiology were obtained from published
clinical trials and studies. The database of the main insurance
fund (IKA) was analysed to estimate the cost of events. The
analysis was done from a payer perspective, all outcomes were
discounted at 3% and prices correspond to 2008. RESULTS: The
estimated patient cost per annum for each health state was: stable
angina: €2252; unstable angina: €2572; myocardial infarction:
€2473; post-MI: €1677; stroke: €12,233; post-stroke: €1240;
heart failure: €2655; angiogram: €1544; angioplasty: €6511;
bypass surgery; €11,514. For the baseline group (age: 57 years,
systolic-blood-pressure: 147, cholesterol: 6.00 mmol/L, BMI:
29 kg/m2) with mild/moderate disease, the total cost was €15,146
with irbesartan, €15,486 with losartan and €15,613 valsartan;
QALYs were 12.67, 12.63 and 12.64, respectively. For the group
with severe disease, the total cost with irbesartan) was €15,798
(150 mg) and €18,697 (300 mg), whilst with Losartan was
€16,295 (50 mg) and €22,496 (100 mg); QALYs were 12.47 and
12.37 for irbesartan and losartan respectively. Thus, irbesartan
was less costly and more effective and dominated the other two
treatments. Similar results were obtained in relation to various
other patient groups and several sensitivity analyses. CONCLU-
SIONS: For different patient populations, irbesartan represents
good value for money in the Greek NHS setting, compared to
selected commonly used alternatives.
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OBJECTIVES: The development of a decision model for the
assessment of the emerging technology implantation of valved
venous conduits (VVC) using tissue engineering in patients with
chronic venous insufﬁciency (CVI) versus Conservative treatment
options like horse chestnut seed extract and compression therapy.
METHODS: The model allows to enter parameters for the efﬁ-
cacy, safety, long-term effectiveness, quality of life, disease-speciﬁc
mortality, and costs and to derive (quality-adjusted) life expect-
ancy and cost-effectiveness from a health care system perspective.
It evaluates a lifelong time horizon using the Gompertz function
and applies an annual discount rate of 3%. Cost and epidemio-
logical data of CVI were gathered from literature. The costs for
VVCwere estimated considering the development costs. Finally to
calculate QALYs we surveyed a panel of angiologists and angio-
surgeons presenting the results of animal studies concerning the
functionality, tolerability and hemorheology. RESULTS: A mar-
ginal difference of 0.04 LY in favor of VVC was calculated
incorporating the lethality of the implantation. VVC yielded
additional QALY gains of 2.02 compared to conservative therapy.
Patient implanted with VVC were estimated to reach a utility of
0.64 comparedwith 0.50 for those receiving conservative therapy.
VVC was in the conservative scenario with implantation of up to
four conduits €4395 more expensive; in the scenario with up to
two implanted conduits the difference was only €330. VVC seems
to be cost-effective for CVI patients, with an incremental cost-
effectiveness ratio compared with conservative therapy of 163 to
€2176/QALY. CONCLUSIONS: Especially in the ﬁeld of emerg-
ing technologies, where data from clinical trials are lacking,
decision-analytic modeling even in a pre-market condition is a
useful tool to systematically assess the expected value of technolo-
gies and the related uncertainty. Thereby, developers can avoid
misdirected investment in health care systems ruled by thresholds
even before the diffusion of a technology.
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OBJECTIVES: To model the impact of the addition of ﬁxed-dose
niacin extended-release and simvastatin (NER/S) therapy to a
health plan formulary in terms of optimal low density lipoprotein
cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-
C), and triglyceride (TG) value attainment. METHODS: Two
hypothetical formularies with all major branded and generic lipid
drugs were modeled over a three year time horizon: a formulary
not including NER/S (current formulary) and a formulary which
did (revised formulary). Primary and secondary risk patients with
1 sub-optimal lipid parameter were sampled from the Health-
Core Integrated Research Database between 1/1/2000 and 2/28/
2005. Package insert efﬁcacy of antihyperlipidemic medications
in each formulary was applied to the sample population. Post-
treatment lipid values were evaluated according to U.S. lipid
guidelines. Rates of individual and combined optimal lipid value
(OLV) [LDL-C, HDL-C, and TG] achievement were estimated in
direct proportion to lipid therapy market shares in both formu-
laries. Changes in clinical outcomes between formularies were
evaluated relative to incremental change in pharmacy and car-
diovascular (CV) disease related medical costs. Market penetra-
tion of NER/S was assumed to be 1.5% and payer discounts of
17% and 50% were applied to branded and generic wholesale
acquisition costs. RESULTS: The rate of combined OLV attain-
ment over three years in the revised formulary increased 0.57%
from the current formulary. Attainment of optimal LDL-C,
HDL-C and TG values increased by 0.07%, 0.30%, and 0.10%,
respectively. The cost for a 1% increase in optimal LDL-C,
HDL-C, and TG attainment was $3103, $952, and $2047
respectively. There was an estimated $1147 cost for every 1%
increase in combined OLV attainment. CONCLUSIONS: The
addition of NER/S to the health plan formulary increases indi-
vidual and combined OLV achievement thereby having the
potential to reduce the incidence of CV events and CV-related
medical costs.
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OBJECTIVES: To evaluate changes in low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-
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C), and triglyceride (TG) goal attainment, annual cardiovascular
disease (CVD)-related health care utilization and costs among
patients initiating combination statin and extended-release niacin
(NER) therapy (S + NER + S). METHODS: A retrospective
cohort study of patients initiating S + ERN between January 1,
2000 and June 30, 2006 was conducted utilizing medical, phar-
macy and laboratory result data from the HealthCore Integrated
Research Database. Patients were primary or secondary risk,
aged 18 years, had 1 lipid laboratory result 12 months prior
to index date, and 12 months pre- and post-index eligibility.
Clinical and economic outcomes were evaluated during the 12
months prior to and after initiation of S + ERN. Lipid goal
attainment was determined based on US national lipid guidelines.
CVD-related resource utilization and costs were annualized post-
index. Change in lipid goal attainment, annual resource utiliza-
tion and costs were tested using Generalized Estimating
Equations (GEE). Model covariates for lipid goal attainment
included age, gender, time to NER addition, and co-morbidity
index. RESULTS: A total of 845 (51% secondary risk) patients
initiating NER + S were identiﬁed. Patients were predominantly
male (77%), mean age 52.6 (9.05) years and time to addition
of NER was 225 (306) days. Mean change in lipid values
(mg/dL) for LDL-C, HDL-C, and TG was (-)10.81  30.67,
2.73  7.24 for HDL-C, and (-)22.67  106.79 respectively.
Multivariate analysis demonstrated increased likelihood of goal
attainment for LDL-C (OR: 1.56; p = 0.0016), HDL-C (OR:
1.58; p = 0.0004), and TG (OR: 1.39; p = 0.0078) after initiation
of NER + S therapy. GEE results demonstrated signiﬁcant
improvement from pre-index in annual CVD attributable
inpatient visits (17  49 vs 9  31 per 100 patients; p < 0.0001)
and total medical cost ($3214  10,282 vs. $2039  7117;
p < 0.0001). CONCLUSIONS: Comprehensive treatment
approach of combination NER + S therapy was associated with
improved change in lipid values, target lipid value attainment,
and reduced CVD-related inpatient visits and total medical cost.
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OBJECTIVES: To model the impact of the addition of ﬁxed-dose
niacin extended-release and simvastatin (NER/S) therapy to a
health plan formulary in terms of cardiovascular (CV) events and
corresponding attributable costs. METHODS: Two hypothetical
formularies with all major branded and generic lipid drugs were
modeled over a three year time horizon: a formulary not includ-
ing NER/S (current formulary) and a formulary which did
(revised formulary). Primary and secondary risk patients with1
sub-optimal lipid parameter were sampled from the HealthCore
Integrated Research Database between 1/1/2000 and 2/28/2005.
Package insert efﬁcacy of antihyperlipidemic medications in each
formulary was applied to the sample population. Changes in
clinical outcomes (combined lipid value attainment of low
density lipoprotein cholesterol, high density lipoprotein choles-
terol, and triglycerides, and CV events) between formularies were
evaluated relative to incremental change in pharmacy and CV
disease-related medical costs. Market penetration of NER/S was
assumed to be 1.5% and payer discounts of 17% and 50% were
applied to brand and generic wholesale acquisition costs.
RESULTS: For every 1% increase in NER/S market share there
was a corresponding 0.38% increase in the incremental rate of
combined OLV achievement and 0.06% decrease in the incre-
mental incidence of CV events between current and revised for-
mularies. Total health system drug expenditure increased by 15%
while CV event costs decreased by 10%. The incremental cost
per CV event avoided was $46,593 and $12,957 per CV event
related hospital day avoided. CONCLUSIONS: The addition of
NER/S to the health plan formulary increases combined optimal
lipid value achievement and correspondingly reduces the three
year incidence of CV events and CV event related costs in this
hypothetical patient population.
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OBJECTIVES: This analysis aims to explore management of
acute coronary syndromes (ACS) from acute event to hospital
discharge in France. METHODS: This 12-month prospective,
observational study recruited ACS patients undergoing percuta-
neous coronary intervention (PCI), January-August 2007,
capturing practice patterns, resource use and quality of life. In
France, all interventional cardiologists were invited to partici-
pate. RESULTS: 497 ACS-PCI patients (483 analyzed), enrolled
by 59 interventional cardiologists from public university
hospitals-36%, public non-university hospitals-45%, and private
hospitals-19%, were: mean age 60.9 +/- 12.8, mean weight
79.7 kg +/- 14.8, 18% female, 16% diabetics and 12% prior
myocardial infarction (MI). Index diagnosis was: unstable angina
or non-ST-elevation MI (UA/NSTEMI)-53% and ST-elevation
MI (STEMI)-47%. Almost all patients (96%) were implanted
stents: 67% bare metal stents (BMS), 23% drug eluting stents
(DES) and 11% both. Antiplatelet loading oral medications used
were aspirin-91% and clopidogrel-95% (no use of ticlopidine).
Antithrombotic agents were infused too: abciximab-16%,
tiroﬁban-18%. eptiﬁbatide-3%, and bivalirudin-3%. Clopi-
dogrel loading dose (LD) was given in intensive care unit-32%,
emergency room-24%, ambulance-21%, previous hospital-12%,
catheter lab-6% and other ward-4%, and close to PCI (previous
6 hours, during or after) in 46% of cases. Total clopidogrel
loading dose was over 300 mg in 34% of cases, and in-hospital
maintenance dose (MD) was 150 mg in 26%, and 75 mg in 74%
of cases. At time of hospital discharge, 96% of patients were
receiving clopidogrel (discharge dose 150 mg in 23%) and
EQ-5D QoL score was a median 0.85 (IQR 0.73–1.00). CON-
CLUSIONS: These data reﬂect contemporary real-life manage-
ment of ACS patients in France. DES are implanted 3 times less
than BMS. Variation in oral antiplatelet agent dosing pattern (LD
and MD) and timing of administration is frequent.
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OBJECTIVES: To collect location of care, resource utilization,
utilities and quality of life data in relation to post-stroke physical
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